Literature DB >> 33856821

Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.

Erin A Vogel1, Neal L Benowitz2, Jordan Skan3, Matthew Schnellbaecher3, Judith J Prochaska1.   

Abstract

Research on nicotine metabolism has primarily focused on white adults. This study examined associations between nicotine metabolism, tobacco use, and demographic characteristics among Alaska Native adults who smoke cigarettes. Participants (N = 244) were Alaska Native adults who smoked and who provided a plasma sample at baseline (70.1%) or follow-up (29.9%) of a randomized controlled trial of a cardiovascular risk behavior intervention. At baseline, participants self-reported age, sex, Alaska Native heritage, cigarettes per day, time to first cigarette upon wakening, menthol use, perceived difficulty staying quit, tobacco withdrawal symptoms, and past-month tobacco product use, binge drinking, and cannabis use. At 3-, 6-, 12-, and 18-month follow-ups, participants self-reported 7-day point prevalence abstinence from smoking. Height and weight were measured to calculate body mass index (BMI). Participants' nicotine metabolite ratio (NMR), calculated as the ratio of plasma cotinine and trans-3' hydroxycotinine, was log-transformed. The sample (52.0% male, age M = 47.0 years [SD = 13.8], 60.3% of Inupiaq heritage) averaged 12.5 cigarettes per day (SD = 10.5); 64.0% smoked within 30 min of wakening. NMR was not significantly associated with age, sex, Alaska Native heritage, BMI, cigarettes per day, time to first cigarette upon wakening, menthol use, perceived difficulty staying quit, past-month dual tobacco product use, withdrawal symptoms, past-month binge drinking, past-month cannabis use, or abstinence from smoking (all p-values > .050). Characteristics that relate to NMR in Alaska Native adults may differ from those typically identified among white adults. Specifically, results may suggest that Alaska Native adults with slower nicotine metabolism do not titrate their nicotine intake when smoking. (PsycInfo Database Record (c) 2022 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33856821      PMCID: PMC8517031          DOI: 10.1037/pha0000461

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.492


  36 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.

Authors:  N L Benowitz; P Jacob; R T Jones; J Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

3.  Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.

Authors:  Dana M Carroll; Sharon E Murphy; Neal L Benowitz; Andrew A Strasser; Michael Kotlyar; Stephen S Hecht; Steve G Carmella; Francis J McClernon; Lauren R Pacek; Sarah S Dermody; Ryan G Vandrey; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-12       Impact factor: 4.254

4.  Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults.

Authors:  Denise B Kandel; Mei-Chen Hu; Christine Schaffran; J Richard Udry; Neal L Benowitz
Journal:  Am J Epidemiol       Date:  2007-02-23       Impact factor: 4.897

5.  Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.

Authors:  Jill C Mwenifumbo; Edward M Sellers; Rachel F Tyndale
Journal:  Drug Alcohol Depend       Date:  2006-12-08       Impact factor: 4.492

6.  Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Authors:  Meghan J Chenoweth; Maria Novalen; Larry W Hawk; Robert A Schnoll; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-10       Impact factor: 4.254

7.  Signs and symptoms of tobacco withdrawal.

Authors:  J R Hughes; D Hatsukami
Journal:  Arch Gen Psychiatry       Date:  1986-03

8.  CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.

Authors:  Matthew J Binnington; Andy Z X Zhu; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

9.  Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence.

Authors:  Evangelia Liakoni; Kathryn C Edwards; Gideon St Helen; Natalie Nardone; Delia A Dempsey; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2018-10-25       Impact factor: 6.875

10.  Stability of the nicotine metabolite ratio in ad libitum and reducing smokers.

Authors:  Marc E Mooney; Zhong-Ze Li; Sharon E Murphy; Paul R Pentel; Chap Le; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

View more
  1 in total

1.  Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion.

Authors:  Paulo Roberto Xavier Tomaz; Thuane Sales Gonçalves; Juliana Rocha Santos; Jaqueline Scholz; Tânia Ogawa Abe; Patrícia Viviane Gaya; Eduardo Costa Figueiredo; Henrique Dipe de Faria; Isarita Martins; Ana Miguel Fonseca Pego; Beatriz Aparecida Bismara; Maurício Yonamine; Alexandre Costa Pereira; Paulo Caleb Júnior Lima Santos
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.